Seroconversion and asymptomatic infections during oseltamivir prophylaxis against Influenza A H1N1 2009

<p>Abstract</p> <p>Background</p> <p>Anti-viral prophylaxis is used to prevent the transmission of influenza. We studied serological confirmation of 2009 Influenza A (H1N1) infections during oseltamivir prophylaxis and after cessation of prophylaxis.</p> <p>...

Full description

Bibliographic Details
Main Authors: Tan Boon, Ho Hanley J, Gao Qiuhan, Barr Ian, Yap Jonathan, Tay Joshua K, Lee Vernon J, Kelly Paul M, Tambyah Paul A, Kelso Anne, Chen Mark I
Format: Article
Language:English
Published: BMC 2010-06-01
Series:BMC Infectious Diseases
Online Access:http://www.biomedcentral.com/1471-2334/10/164
id doaj-d4738bdd2fc94fcdb899700807fc4709
record_format Article
spelling doaj-d4738bdd2fc94fcdb899700807fc47092020-11-25T03:48:50ZengBMCBMC Infectious Diseases1471-23342010-06-0110116410.1186/1471-2334-10-164Seroconversion and asymptomatic infections during oseltamivir prophylaxis against Influenza A H1N1 2009Tan BoonHo Hanley JGao QiuhanBarr IanYap JonathanTay Joshua KLee Vernon JKelly Paul MTambyah Paul AKelso AnneChen Mark I<p>Abstract</p> <p>Background</p> <p>Anti-viral prophylaxis is used to prevent the transmission of influenza. We studied serological confirmation of 2009 Influenza A (H1N1) infections during oseltamivir prophylaxis and after cessation of prophylaxis.</p> <p>Methods</p> <p>Between 22 Jun and 16 Jul 09, we performed a cohort study in 3 outbreaks in the Singapore military where post-exposure oseltamivir ring chemoprophylaxis (75 mg daily for 10 days) was administered. The entire cohort was screened by RT-PCR (with HA gene primers) using nasopharyngeal swabs three times a week. Three blood samples were taken for haemagglutination inhibition testing - at the start of outbreak, 2 weeks after completion of 10 day oseltamivir prophylaxis, and 3 weeks after the pandemic's peak in Singapore. Questionnaires were also administered to collect clinical symptoms.</p> <p>Results</p> <p>237 personnel were included for analysis. The overall infection rate of 2009 Influenza A (H1N1) during the three outbreaks was 11.4% (27/237). This included 11 index cases and 16 personnel (7.1%) who developed four-fold or higher rise in antibody titres during oseltamivir prophylaxis. Of these 16 personnel, 8 (3.5%) were symptomatic while the remaining 8 personnel (3.5%) were asymptomatic and tested negative on PCR. Post-cessation of prophylaxis, an additional 23 (12.1%) seroconverted. There was no significant difference in mean fold-rise in GMT between those who seroconverted during and post-prophylaxis (11.3 vs 11.7, p = 0.888). No allergic, neuropsychiatric or other severe side-effects were noted.</p> <p>Conclusions</p> <p>Post-exposure oseltamivir prophylaxis reduced the rate of infection during outbreaks, and did not substantially increase subsequent infection rates upon cessation. Asymptomatic infections occur during prophylaxis, which may confer protection against future infection. Post-exposure prophylaxis is effective as a measure in mitigating pandemic influenza outbreaks.</p> http://www.biomedcentral.com/1471-2334/10/164
collection DOAJ
language English
format Article
sources DOAJ
author Tan Boon
Ho Hanley J
Gao Qiuhan
Barr Ian
Yap Jonathan
Tay Joshua K
Lee Vernon J
Kelly Paul M
Tambyah Paul A
Kelso Anne
Chen Mark I
spellingShingle Tan Boon
Ho Hanley J
Gao Qiuhan
Barr Ian
Yap Jonathan
Tay Joshua K
Lee Vernon J
Kelly Paul M
Tambyah Paul A
Kelso Anne
Chen Mark I
Seroconversion and asymptomatic infections during oseltamivir prophylaxis against Influenza A H1N1 2009
BMC Infectious Diseases
author_facet Tan Boon
Ho Hanley J
Gao Qiuhan
Barr Ian
Yap Jonathan
Tay Joshua K
Lee Vernon J
Kelly Paul M
Tambyah Paul A
Kelso Anne
Chen Mark I
author_sort Tan Boon
title Seroconversion and asymptomatic infections during oseltamivir prophylaxis against Influenza A H1N1 2009
title_short Seroconversion and asymptomatic infections during oseltamivir prophylaxis against Influenza A H1N1 2009
title_full Seroconversion and asymptomatic infections during oseltamivir prophylaxis against Influenza A H1N1 2009
title_fullStr Seroconversion and asymptomatic infections during oseltamivir prophylaxis against Influenza A H1N1 2009
title_full_unstemmed Seroconversion and asymptomatic infections during oseltamivir prophylaxis against Influenza A H1N1 2009
title_sort seroconversion and asymptomatic infections during oseltamivir prophylaxis against influenza a h1n1 2009
publisher BMC
series BMC Infectious Diseases
issn 1471-2334
publishDate 2010-06-01
description <p>Abstract</p> <p>Background</p> <p>Anti-viral prophylaxis is used to prevent the transmission of influenza. We studied serological confirmation of 2009 Influenza A (H1N1) infections during oseltamivir prophylaxis and after cessation of prophylaxis.</p> <p>Methods</p> <p>Between 22 Jun and 16 Jul 09, we performed a cohort study in 3 outbreaks in the Singapore military where post-exposure oseltamivir ring chemoprophylaxis (75 mg daily for 10 days) was administered. The entire cohort was screened by RT-PCR (with HA gene primers) using nasopharyngeal swabs three times a week. Three blood samples were taken for haemagglutination inhibition testing - at the start of outbreak, 2 weeks after completion of 10 day oseltamivir prophylaxis, and 3 weeks after the pandemic's peak in Singapore. Questionnaires were also administered to collect clinical symptoms.</p> <p>Results</p> <p>237 personnel were included for analysis. The overall infection rate of 2009 Influenza A (H1N1) during the three outbreaks was 11.4% (27/237). This included 11 index cases and 16 personnel (7.1%) who developed four-fold or higher rise in antibody titres during oseltamivir prophylaxis. Of these 16 personnel, 8 (3.5%) were symptomatic while the remaining 8 personnel (3.5%) were asymptomatic and tested negative on PCR. Post-cessation of prophylaxis, an additional 23 (12.1%) seroconverted. There was no significant difference in mean fold-rise in GMT between those who seroconverted during and post-prophylaxis (11.3 vs 11.7, p = 0.888). No allergic, neuropsychiatric or other severe side-effects were noted.</p> <p>Conclusions</p> <p>Post-exposure oseltamivir prophylaxis reduced the rate of infection during outbreaks, and did not substantially increase subsequent infection rates upon cessation. Asymptomatic infections occur during prophylaxis, which may confer protection against future infection. Post-exposure prophylaxis is effective as a measure in mitigating pandemic influenza outbreaks.</p>
url http://www.biomedcentral.com/1471-2334/10/164
work_keys_str_mv AT tanboon seroconversionandasymptomaticinfectionsduringoseltamivirprophylaxisagainstinfluenzaah1n12009
AT hohanleyj seroconversionandasymptomaticinfectionsduringoseltamivirprophylaxisagainstinfluenzaah1n12009
AT gaoqiuhan seroconversionandasymptomaticinfectionsduringoseltamivirprophylaxisagainstinfluenzaah1n12009
AT barrian seroconversionandasymptomaticinfectionsduringoseltamivirprophylaxisagainstinfluenzaah1n12009
AT yapjonathan seroconversionandasymptomaticinfectionsduringoseltamivirprophylaxisagainstinfluenzaah1n12009
AT tayjoshuak seroconversionandasymptomaticinfectionsduringoseltamivirprophylaxisagainstinfluenzaah1n12009
AT leevernonj seroconversionandasymptomaticinfectionsduringoseltamivirprophylaxisagainstinfluenzaah1n12009
AT kellypaulm seroconversionandasymptomaticinfectionsduringoseltamivirprophylaxisagainstinfluenzaah1n12009
AT tambyahpaula seroconversionandasymptomaticinfectionsduringoseltamivirprophylaxisagainstinfluenzaah1n12009
AT kelsoanne seroconversionandasymptomaticinfectionsduringoseltamivirprophylaxisagainstinfluenzaah1n12009
AT chenmarki seroconversionandasymptomaticinfectionsduringoseltamivirprophylaxisagainstinfluenzaah1n12009
_version_ 1724496784082862080